Supernus Pharmaceuticals, a former Shire sub developing improved drug formulations for epilepsy and ADHD, raised $50 million on Monday by offering 10 million shares at $5. The company had originally filed to offer 5.8 million shares at a range of $12 to $14 before filing an amendment last Friday revising deal terms to 11 million shares at an estimated listing price of $5. Supernus Pharmaceuticals plans to list on the NASDAQ under the symbol SUPN. Citi acted as lead manager on the deal.
